13 results about "Cytisine" patented technology

The invention discloses an Escherichia coli mutant strain which is classified and named as Escherichia coli, the strain number is CR-TK01, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35554. The invention further discloses a preparation method of the Escherichia coli mutant strain. The Escherichia coli CR-TK01 with high yield of cytidine provided by the invention has the characteristics of high yield and stable high-yield character, glucose is used as a carbon source, the Escherichia coli CR-TK01 is used for fermentation production of cytidine under a certain fermentation condition, and the yield of cytidine is as high as 97.23 g / L; the strain is not degraded after passage for more than 20 generations, the performance of high-yield cytidine is maintained in the passage fermentation process, and the yield of cytidine in passage fermentation is improved. The method for producing cytidine through fermentation is simple in process, high in yield and suitable for industrialization.

The invention discloses application of a cytisine type alkaloid and a derivative thereof in preparation of a medicine for preventing or treating respiratory syncytial virus infection, and relates to the technical field of respiratory syncytial virus prevention and treatment. The research finds that the natural product cytisine shows good anti-respiratory syncytial virus infection activity in vivo and in vitro, and finds that the cytisine can obviously relieve lung injury caused by virus infection and reduce lung inflammation; the invention provides an experimental basis for developing an efficient and safe drug for resisting respiratory syncytial virus (RSV) infection. As a natural product, the cytisine reduces the social burden caused by treatment of respiratory syncytial virus infection and reduces the treatment cost.

The invention provides a green synthesis method of an alpha-aminoketone compound based on visible light catalytic oxidation amination reaction, and belongs to the technical field of organic chemical synthesizing.According to the method, aliphatic aldehyde and secondary amine which are low in price and easy to obtain serve as raw materials, oxygen serves as a green terminal oxidizing agent, and the alpha-aminoketone compound is synthesized under normal temperature and visible light irradiation. The alpha-aminoketone compound is efficiently synthesized in one step through oxidative amination reaction catalyzed by organic photosensitizers such as rhodamine 6G and anthraquinone. According to the method, a noble metal catalyst and a stoichiometric oxidant are abandoned, the reaction condition is mild (room temperature), the operation is simple and convenient, the substrate application range is wide, and the method shows excellent compatibility to functional groups including various complex cyclic secondary amines (such as natural product derivatives of nornicotine, cytisine and the like); compared with the prior art, the method has the advantages that important transformation from thermal activation to light activation is realized on the reaction mechanism, and a novel green way which is more economical and environment-friendly and is easy for large-scale production is provided for synthesis of alpha-aminoketone.

The present invention relates to a transdermal therapeutic system (TTS) for transdermal administration of cytisine, the transdermal therapeutic system comprising a self-adhesive layer structure comprising a therapeutically effective amount of cytisine, such cytisine TTS for use in a method of treatment and a method for making such cytisine TTS.

Methods for the treatment of addiction and / or dependence are provided, methods to promote the cessation of various addictions, such as smoking and / or vaping, and methods to promote a reduction of various addictions, such as smoking and / or vaping, uses of cytisine as a treatment to quit addiction and dosage regimens for the above.

Salts of cytisine have been prepared and incorporated in stable pharmaceutical compositions, including compositions comprising lactose. The salts are prepared by adding acid stock solutions to solutions of cytisine with heating, followed by cooling to ambient temperature. The salts and compositions are indicated in the treatment of nicotine addiction.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH regulator selected from the group consisting of inorganic acids, inorganic buffers, and salts of inorganic acids, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention also relates to the liquid pharmaceutical composition for use in the treatment of tobacco addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco addiction and other forms of nicotine addiction.

A unit dosage comprising a succinate salt of cytisine formulated as a pharmaceutical composition further comprising a pharmaceutically acceptable excipient, and use in treating a nicotine addiction.

The application provides an antitumor delphinine alkaloid in Caesalpinia minax, a core skeleton of angustifoline type, and provides an extraction method and application, and compound 3 is used for preparation of an antitumor drug. The natural delphinine with a new angustifoline type structural skeleton is obtained by separation and extraction, wherein compound 3 has a significant inhibitory effect on multiple tumor cell strains, and can be used for preparation of an antitumor drug.